Susquehanna Fundamental Investments’s Novo Nordisk NVO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-58,124	Closed	-$4.62M	–	807
2023 Q1	$4.62M	Hold	58,124	–	–	0.11%	235
2022 Q4	$3.93M	Sell	58,124 -23,656	-29%	-$1.39M	0.07%	347
2022 Q3	$4.07M	Buy	+81,780	New	+$4.38M	0.07%	369
2022 Q1	$6.89M	Sell	124,040 -24,900	-17%	-$1.28M	0.13%	215
2021 Q4	$8.34M	Hold	148,940	–	–	0.22%	109
2021 Q3	$7.15M	Buy	148,940 +70,100	+89%	+$3.39M	0.13%	201
2021 Q2	$3.3M	Sell	78,840 -26,530	-25%	-$1.03M	0.06%	438
2021 Q1	$3.55M	Sell	105,370 -150,922	-59%	-$5.38M	0.06%	443
2020 Q4	$8.95M	Buy	256,292 +36,364	+17%	+$1.26M	0.16%	163
2020 Q3	$7.63M	Sell	219,928 -109,000	-33%	-$3.63M	0.23%	100
2020 Q2	$10.8M	Buy	328,928 +98,600	+43%	+$3.15M	0.51%	28
2020 Q1	$6.93M	Buy	230,328 +107,728	+88%	+$3.21M	1.38%	10
2019 Q4	$3.55M	Buy	122,600 +7,200	+6%	+$199K	0.46%	70
2019 Q3	$2.98M	Buy	+115,400	New	+$2.92M	0.36%	81

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna Fundamental Investments's NVO Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of Novo Nordisk (NVO) in Q2 2023, closing a stake of 58,124 shares — an estimated $4.62M sold.

Susquehanna Fundamental Investments first reported a position in NVO in Q3 2019 and held it in 14 quarters. The position peaked at $10.8M in Q2 2020. 1,198 funds tracked by Wall St. Rank hold NVO as of Q2 2023.

Susquehanna Fundamental Investments reported no remaining Novo Nordisk position as of Q2 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 58,124 Novo Nordisk shares in Q2 2023, an estimated $4.62M.
Susquehanna Fundamental Investments first reported a position in Novo Nordisk in Q3 2019 and held it in 14 quarters.
Susquehanna Fundamental Investments's Novo Nordisk position peaked at $10.8M in Q2 2020.
1,198 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.